Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial

Nidom CA(2010)Influenza A (H5N1) viruses from pigs, Indonesia Emerg Infect Dis 16 1515-23

Takano R(2009)Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 MMWR 58 1-52

Yamada S(2007)Commentary: from scarcity to abundance: pandemic vaccines and other agents for ‘have not’ countries J Public Health Policy 28 322-340

Sakai-Tagawa Y(2007)Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine Lancet 370 580-89

Daulay S(2008)Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine PLoS One 3 e1665-88

Aswadi D(2008)Crossprotection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine PLoS One 3 e1401-35

Suzuki T(2008)Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial Vaccine 26 2378-677

Suzuki Y(2009)Immunogenicity and tolerability of an AS03-adjuvanted prepandemic influenza vaccine. A phase III study in a large population of Asian adults Vaccine 27 7428-13

Shinya K(2010)AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged up to 85 years Clin Infect Dis 51 668-35

Iwatsuki-Horimoto K(2009)Response to a monovalent 2009 influenza A (H1N1) vaccine N Engl J Med 361 2405-8

Nidom CA(2010)Influenza A (H5N1) viruses from pigs, Indonesia Emerg Infect Dis 16 1515-23

Takano R(2009)Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 MMWR 58 1-52

Yamada S(2007)Commentary: from scarcity to abundance: pandemic vaccines and other agents for ‘have not’ countries J Public Health Policy 28 322-340

Sakai-Tagawa Y(2007)Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine Lancet 370 580-89

Daulay S(2008)Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine PLoS One 3 e1665-88

Aswadi D(2008)Crossprotection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine PLoS One 3 e1401-35

Suzuki T(2008)Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial Vaccine 26 2378-677

Suzuki Y(2009)Immunogenicity and tolerability of an AS03-adjuvanted prepandemic influenza vaccine. A phase III study in a large population of Asian adults Vaccine 27 7428-13

Shinya K(2010)AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged up to 85 years Clin Infect Dis 51 668-35

Iwatsuki-Horimoto K(2009)Response to a monovalent 2009 influenza A (H1N1) vaccine N Engl J Med 361 2405-8